Characterization of the role of Samsn1 loss in multiple myeloma development-Reference-Cited by-同舟云学术

Characterization of the role of Samsn1 loss in multiple myeloma development

Published:2020-08-05 Issue:9 Volume:2 Page:554-572
ISSN:2573-9832
Container-title:FASEB BioAdvances
language:en
Short-container-title:FASEB BioAdvances

Author:

Friend Natasha L.¹²,Hewett Duncan R.¹²,Panagopoulos Vasilios¹²,Noll Jacqueline E.¹²,Vandyke Kate¹²,Mrozik Krzysztof M.¹²,Fitter Stephen¹²,Zannettino Andrew C.W.¹²³

Affiliation:

1. Myeloma Research Laboratory Adelaide Medical School Faculty of Health and Medical Sciences University of Adelaide Adelaide Australia

2. Precision Medicine Theme South Australian Health and Medical Research Institute Adelaide Australia

3. Central Adelaide Local Health Network Adelaide Australia

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fba.2020-00027

Reference98 articles.

1. Multiple Myeloma

2. Multiple myeloma

3. Multiple myeloma

4. Multiple myeloma epidemiology and survival: A unique malignancy

5. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts;Frontiers in Oncology;2024-07-02

2. Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts;2024-05-04

3. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines;Leukemia Research;2024-04

4. Immunocompetent Mouse Models of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?;Frontiers in Immunology;2021-01-20